The Impact of Concurrent Proton Pump Inhibitors on Nivolumab Response in Metastatic Non-Small Cell Lung Cancer: A Multicenter Real-Life Study

<i>Background and Objectives</i>: Clinically meaningful drug–drug interactions may be overlooked in oncology. Proton pump inhibitors (PPIs) may modulate outcomes with immune checkpoint inhibitors (ICIs) by altering the gut microbiome, altering the immune milieu, and affecting transporter interaction...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Engin Hendem, Mehmet Zahid Koçak, Ayşegül Merç Çetinkaya, Gülhan Dinç, Melek Çağlayan, Muzaffer Uğraklı, Dilek Çağlayan, Murat Araz, Melek Karakurt Eryılmaz, Abdullah Sakin, Orhan Önder Eren, Ali Murat Tatlı, Çağlayan Geredeli, Mehmet Artaç
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	MDPI AG 2026-01-01
Sarja:	Medicina
Aiheet:	proton pump inhibitors nivolumab Carcinoma non-small-cell lung progression-free survival overall survival
Linkit:	https://www.mdpi.com/1648-9144/62/1/214
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!